XML 116 R101.htm IDEA: XBRL DOCUMENT
v3.25.1

Business Segments (Revenue by Product) (Details) - USD ($) $ in Thousands | 12 Months Ended
--- | ---
Mar. 31, 2025 | Mar. 31, 2024 | Mar. 31, 2023
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | $ 1,137,762 | $ 1,125,357 | $ 1,127,725
Analgesics |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 117,697 | 117,451 | 119,262
Cough & Cold |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 106,214 | 119,020 | 126,988
Women's Health |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 236,831 | 240,421 | 251,351
Gastrointestinal |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 255,943 | 231,610 | 226,583
Eye & Ear Care |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 183,322 | 179,423 | 171,076
Dermatologicals |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 128,947 | 129,102 | 123,741
Oral Care |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 95,030 | 96,305 | 97,627
Other OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 13,778 | 12,025 | 11,097
North American OTC Healthcare |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 960,010 | 958,260 | 973,774
North American OTC Healthcare | Analgesics |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 112,173 | 111,996 | 116,582
North American OTC Healthcare | Cough & Cold |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 82,533 | 93,575 | 100,218
North American OTC Healthcare | Women's Health |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 216,335 | 217,103 | 231,754
North American OTC Healthcare | Gastrointestinal |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 174,891 | 160,889 | 156,957
North American OTC Healthcare | Eye & Ear Care |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 158,858 | 156,553 | 151,879
North American OTC Healthcare | Dermatologicals |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 120,770 | 123,288 | 119,822
North American OTC Healthcare | Oral Care |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 81,868 | 83,212 | 85,542
North American OTC Healthcare | Other OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 12,582 | 11,644 | 11,020
International OTC Healthcare |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 177,752 | 167,097 | 153,951
International OTC Healthcare | Analgesics |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 5,524 | 5,455 | 2,680
International OTC Healthcare | Cough & Cold |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 23,681 | 25,445 | 26,770
International OTC Healthcare | Women's Health |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 20,496 | 23,318 | 19,597
International OTC Healthcare | Gastrointestinal |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 81,052 | 70,721 | 69,626
International OTC Healthcare | Eye & Ear Care |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 24,464 | 22,870 | 19,197
International OTC Healthcare | Dermatologicals |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 8,177 | 5,814 | 3,919
International OTC Healthcare | Oral Care |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | 13,162 | 13,093 | 12,085
International OTC Healthcare | Other OTC |  |  |
Revenue from External Customer [Line Items] |  |  |
Total segment revenues | $ 1,196 | $ 381 | $ 77

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=pbh_AnalgesicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pbh_CoughAndColdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pbh_WomensHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pbh_GastrointestinalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pbh_EyeAndEarCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pbh_DermatologicalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pbh_OralCareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=pbh_OtherOtcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pbh_NorthAmericanOTCHealthcareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=pbh_InternationalOTCHealthcareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |